29-MAY-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     4014 370 189 95 30 6 02/06/2019 473 184
Screened at PD     1500 229 128 71 21 4      
Pre-Screened prior to PD     2491 122 51 21 7 1      
Treatment-naive     23 19 10 3 2 1      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     533 28 14 7 1 1      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2192 296 164 91 31 10      
Screened at PD     1271 227 135 77 25 8      
Pre-Screened prior to PD     841 48 17 10 4 0      
Treatment-naive     23 19 10 3 2 2      
After PD on a Lung_MAP Sub-Study     57 2 2 1 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     386 255 141 82 26 8      
S1900G     37 7 4 3 2 0      
S1900J     18 7 4 1 0 0      
S1900K     41 27 15 5 3 2      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     629 123 75 38 9 3      
Initial sub-study registrations     617 123 75 38 9 3      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 99 97 61 33 7 3 05/22/2025 351 115
Docetaxel plus Ramucirumab Y   51 50 31 17 3 1      
Cemiplimab plus Docetaxel and Ramucirumab Y   48 47 30 16 4 2      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   44 26 6 3 2 1 0 05/05/2023 343 109
Capmatinib + Osimertinib + Ramucirumab Y   14 4 1 0 0 0      
Capmatinib + Osimertinib Y   12 2 2 2 1 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 2 1 1 0 0 11/19/2024 285 84
Amivantamab Hyaluronidase Y   4 2 1 1 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 26 18 10 2 1 0 08/08/2024 271 89
Tepotinib + Ramucirumab Y   17 11 7 1 1 0      
Tepotinib Y   9 7 3 1 0 0